LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Tourmaline Bio (TRML – Research Report) today and set a price target of $58.00.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Rami Katkhuda has given his Buy rating due to a combination of factors that highlight the potential of Tourmaline Bio’s pacibekitug as a promising IL-6 inhibitor in the treatment of ASCVD. The ongoing Phase II TRANQUILITY study is expected to provide crucial data on the safety and efficacy of pacibekitug, particularly its ability to reduce hsCRP levels in patients with CKD Stage 3/4. The successful achievement of these endpoints could position pacibekitug as a competitive option in the ASCVD market, especially given its prior success in reducing hsCRP in other chronic inflammatory conditions.
Additionally, the scarcity of IL-6 inhibitors in development for ASCVD presents a significant commercial opportunity for Tourmaline. The potential for pacibekitug to be a best-in-class treatment, combined with the anticipated positive outcomes from related studies, supports the Buy rating. Furthermore, the expected validation of the IL-6 inhibitor class through upcoming trials, such as Novo’s CVOT with zilvekimab, adds to the optimism surrounding Tourmaline’s prospects in this therapeutic area.
According to TipRanks, Katkhuda is a 4-star analyst with an average return of 13.1% and a 36.09% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., VYNE Therapeutics, and Tourmaline Bio.
In another report released on May 5, Leerink Partners also maintained a Buy rating on the stock with a $49.00 price target.